NASDAQ:IPHA Innate Pharma (IPHA) Stock Price, News & Analysis $2.31 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.31▼$2.3450-Day Range$1.99▼$2.4452-Week Range$1.81▼$3.15Volume1,695 shsAverage Volume8,952 shsMarket Capitalization$187.03 millionP/E RatioN/ADividend YieldN/APrice Target$9.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Innate Pharma alerts: Email Address Innate Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside322.1% Upside$9.75 Price TargetShort InterestBearish0.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.15 out of 5 starsMedical Sector731st out of 910 stocksBiological Products, Except Diagnostic Industry122nd out of 155 stocks 3.5 Analyst's Opinion Consensus RatingInnate Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInnate Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Innate Pharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.08% of the outstanding shares of Innate Pharma have been sold short.Short Interest Ratio / Days to CoverInnate Pharma has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Innate Pharma has recently increased by 3.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInnate Pharma does not currently pay a dividend.Dividend GrowthInnate Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPHA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Innate Pharma this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innate Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.16% of the stock of Innate Pharma is held by institutions.Read more about Innate Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Innate Pharma are expected to grow in the coming year, from ($0.94) to ($0.84) per share.Price to Book Value per Share RatioInnate Pharma has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Innate Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Innate Pharma Stock (NASDAQ:IPHA)Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Read More IPHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPHA Stock News HeadlinesSeptember 5 at 5:58 AM | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business UpdateSeptember 4 at 1:00 AM | businesswire.comInnate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …June 17, 2024 | businesswire.comInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 TrialJune 4, 2024 | businesswire.comInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesMay 28, 2024 | businesswire.comInnate Pharma Announces Its Participation in Upcoming Investor ConferencesMay 24, 2024 | businesswire.comInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual MeetingMay 23, 2024 | businesswire.comOutcome of Innate Pharma's 2024 Annual General MeetingSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …May 21, 2024 | businesswire.comInnate Pharma: Clarification Regarding SAR443579 DesignationMay 16, 2024 | markets.businessinsider.comInnate Pharma Buy Rating Affirmed Amid Robust Pipeline and Financial StabilityMay 15, 2024 | businesswire.comInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressMay 14, 2024 | finance.yahoo.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 14, 2024 | businesswire.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 7, 2024 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateApril 15, 2024 | businesswire.comInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsApril 15, 2024 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024April 10, 2024 | businesswire.comInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateSee More Headlines Receive IPHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Next Earnings (Confirmed)9/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IPHA CUSIPN/A CIK1598599 Webwww.innate-pharma.com Phone33-4-30-30-30-30FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$11.50 Low Stock Price Target$8.00 Potential Upside/Downside+322.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.60 Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual Sales$51.90 million Price / Sales3.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book3.35Miscellaneous Outstanding Shares80,967,000Free Float55,147,000Market Cap$187.03 million OptionableNot Optionable Beta0.39 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Herve Brailly Ph.D. (Age 63)Co-Founder, Interim CEO & Chairman of Executive Board Mr. Yannis Morel Ph.D. (Age 51)Executive VP, COO & Member of Executive Board Comp: $390.87kDr. François Romagné Ph.D. (Age 60)Founder Mr. Eric Vivier D.V.M. (Age 60)M.B.A., Ph.D., Founder, Senior VP & Chief Scientific Officer Dr. Marc Bonneville Ph.D. (Age 64)Founder Mr. Jean Jacques Fournié Ph.D.FounderMr. Alessandro Moretta M.D.Ph.D., FounderMr. Frederic Lombard M.B.A. (Age 49)Senior VP & CFO Dr. Sonia Quaratino M.D. (Age 57)Ph.D., Executive VP, Chief Medical Officer & Member of Executive Board Mr. Arvind SoodExecutive VP, President of US Operations & Member of Executive BoardMore ExecutivesKey CompetitorsORIC PharmaceuticalsNASDAQ:ORICReplimune GroupNASDAQ:REPLWave Life SciencesNASDAQ:WVEApplied TherapeuticsNASDAQ:APLTHumacyteNASDAQ:HUMAView All Competitors IPHA Stock Analysis - Frequently Asked Questions How have IPHA shares performed this year? Innate Pharma's stock was trading at $2.80 at the beginning of 2024. Since then, IPHA shares have decreased by 17.5% and is now trading at $2.31. View the best growth stocks for 2024 here. What is Hervé Brailly's approval rating as Innate Pharma's CEO? 4 employees have rated Innate Pharma Chief Executive Officer Hervé Brailly on Glassdoor.com. Hervé Brailly has an approval rating of 100% among the company's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Innate Pharma IPO? Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Innate Pharma? Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Innate Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO) and Gilead Sciences (GILD). This page (NASDAQ:IPHA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.